Stellular Bio, Inc.
Capital Timeline
Capital this company has received, each line traceable to a primary record. Amounts are obligations, not contract ceilings.
A blank stage means the data is not ingested yet, not that the money stopped there.
Across the lifetime of these contracts, $356K has been obligated and $356K paid out. $0 has not been disbursed.
Cumulative from contract start through 2026-08-17. The total above covers only the transactions ingested in the tracking window — a different measure.
- National Institutes of Health$01
Why It Matters
Not enough signal yet to assess this company's relevance to Japanese firms.
Events
Events used as evidence for Stage / LCI. Facts and interpretation are recorded separately.
STELLULAR BIO, INC. — Grant R44EY037132
SCALE-UP AND MANUFACTURING OF STLR-201, AN OFF-THE-SHELF REGENERATIVE THERAPEUTIC FOR SJOGREN'S SYNDROME-RELATED DRY EYE DISEASE - PROJECT SUMMARY: SJOGREN’S SYNDROME-RELATED DRY EYE (SSDE), AFFECTS ABOUT TWO MILLION PEOPLE IN THE U.S. AND ARISES FROM AN AUTOIMMUNE DISORDER THAT DAMAGES THE LACRIMAL GLANDS. A CASCADE OF PATHOLOGICAL CHANGES PERPETUATES AND ADVANCES CORNEAL DAMAGE, RESULTING IN PAIN, BLURRED VISION, AND PHOTOSENSITIVITY THAT MAKES IT DIFFICULT TO PERFORM DAILY FUNCTIONS, RESULTING IN REDUCED WORK PRODUCTIVITY AND A GREATLY REDUCED QUALITY OF LIFE. MOST THERAPIES ONLY TEMPORARILY TREAT SYMPTOMS, AND THE UNDERLYING SSDE CAN CONTINUE TO PROGRESS. IN ADDITION, SOME TREATMENTS ARE SLOW TO TAKE EFFECT AND HAVE SIDE EFFECTS, MAKING THEM LESS APPEALING TO PATIENTS. SEVERAL DISEASE-MODIFYING THERAPIES HAVE SHOWN PROMISE AGAINST DRY EYE DISEASE IN GENERAL, INCLUDING AUTOLOGOUS BLOOD PRODUCTS; HOWEVER, THESE AUTOLOGOUS PRODUCTS ARE PATIENT-SPECIFIC, REQUIRING INDIVIDUALIZED MANUFA
Timeline
No timeline articles for this company yet.